In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Markus BitzerDepartment of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Funding
The Impact of COVID-19 on People Living with Rare Diseases and Their FamiliesU2CTR002818 · NCATS · CINCINNATI CHILDRENS HOSP MED CTR · PI Maurizio Macaluso, Michael Wagner · 2019 to 2026
$51.2MCentral Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1MTraining Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2009 to 2023
$20.3MKPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4MIntegrated spatial interrogation of cellular and molecular signatures of human kidney diseaseU01DK114923 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Tarek Maurice Ashkar, Pierre C Dagher · 2022 to 2026
$5.4MSingle cell multiomic and spatial atlas of acute and chronic kidney injuryU01DK114933 · NIDDK · WASHINGTON UNIVERSITY · PI Sanjay Jain · 2022 to 2026
$5.0MSpatial Multi-Omics to Profile Metabolic Pathways for Kidney DiseaseU01DK114920 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Christopher R Anderton, Kumar Sharma · 2022 to 2026
$3.9MBoston Chronic Kidney Disease Research Biopsy CenterU01DK133092 · NIDDK · BOSTON MEDICAL CENTER · PI Sylvia E Rosas, Sushrut S. Waikar · 2022 to 2026
$3.5MMultimodal Imaging Mass Spectrometry and Spatial Omics for the Human KidneyU01DK133766 · NIDDK · VANDERBILT UNIVERSITY · PI Jeffrey M Spraggins · 2022 to 2026
$3.4MPREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)U01DK114907 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nir Hacohen, Jeffrey Benton Hodgin · 2022 to 2026
$3.2MUniversity of Illinois at Chicago KPMP CKD Recruitment SiteU01DK133081 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JAMES P. LASH, Ana Catherine Ricardo · 2022 to 2026
$2.7MAKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)U01DK114866 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Chirag R Parikh · 2022 to 2026
$2.6MNCATS NIH HHS U2C TR002818NHGRI NIH HHS R01 HG012871NIDDK NIH HHS F32 DK122766NIDDK NIH HHS R01 DK100449NIDDK NIH HHS R21 DK126329NIDDK NIH HHS U01 DK114866NIDDK NIH HHS U01 DK114907NIDDK NIH HHS U01 DK114908NIDDK NIH HHS U01 DK114920NIDDK NIH HHS U01 DK114923NIDDK NIH HHS U01 DK114933NIDDK NIH HHS U01 DK133081NIDDK NIH HHS U01 DK133090NIDDK NIH HHS U01 DK133091NIDDK NIH HHS U01 DK133092NIDDK NIH HHS U01 DK133093NIDDK NIH HHS U01 DK133095NIDDK NIH HHS U01 DK133097NIDDK NIH HHS U01 DK133113NIDDK NIH HHS U01 DK133766NIDDK NIH HHS U01 DK133768NIDDK NIH HHS U24 DK114886NIDDK NIH HHS U54 DK083912NIDDK NIH HHS UH3 DK114861NIDDK NIH HHS UH3 DK114915NIDDK NIH HHS UH3 DK114926NIDDK NIH HHS UH3 DK114937
6 · The paper itselfAbstract
Allele-specific expression (ASE), the preferential expression of one gene copy, is a key mechanism of genomic regulation. However, its role in human kidney disease remains poorly understood. In this study, we generated a high-quality, genome-wide ASE map using paired whole-genome sequencing and RNA sequencing from microdissected glomerular and tubulointerstitial compartments of patients with proteinuric kidney disease. We showed that the majority of common ASE events were deterministic and sequence-mediated. We also found that diseased kidneys exhibited significantly more ASE in glomeruli (GLOM) than tubulointerstitium (TUBE) compared to controls. Unexpectedly, higher ASE in GLOM than TUBE was significantly associated with improved kidney disease outcomes in the disease cohort. Differential gene expression analysis suggested that this was the result of an active, protective transcriptional response, including ribosome and adenosine 5'-triphosphate synthesis up-regulation, rather than pathogenic dysregulation. Our work reveals glomerular ASE as a marker of adaptive transcriptional activity in proteinuric kidney disease.
Indexed as
AllelesGene Expression RegulationKidneyKidney DiseasesFemaleGene Expression ProfilingHumansKidney GlomerulusMale
Identifiers
PMID42826188
PMCPMC13632730
What Socratic holds
Textmetadata
Read underepoch 390